A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of ENV8058 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of ENV8058 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Dec 2015

At a glance

  • Drugs TAK 058 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 16 Dec 2015 Number of treatment arms changed from 6 to 7 with different doses of TAK 058 as reported by ClinicalTrials.gov.
    • 20 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jun 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top